cbd-cannabis-bottles-michael-king-cannabis

Plant-Derived Marijuana Medicine Now Available in Us Pharmacies

Washington, DC: Epidiolex, a prescription medicine containing a standardized formulation of the plant-derived cannabidiol (CBD), is now available in pharmacies in all 50 states.

The US Food and Drug Administration approved the product in June for the explicit treatment of two rare forms of severe epilepsy: Lennox-Gastaut syndrome and Dravet syndrome. In September, the US Drug Enforcement Administration reclassified it from Schedule I to Schedule V – the lowest restriction classification available under federal law. Physicians, at their discretion, may also elect to prescribe the medicine “off-label” for medical conditions other than epilepsy.

An annual prescription for Epidiolex is estimated to cost $32,500 per year, a price that the manufacturer says is “in line with other FDA-approved anti-epileptic drugs.”

Epidiolex is the fourth marijuana-based medicine to receive FDA approval – joining dronabinol (aka Marinol), nabilone (aka Cesamet), and liquid synthetic THC (aka Syndros). However, Epidiolex is the first FDA-approved medicine containing plant-derived non-synthetic cannabinoids

Read More
marijuana-mental-health-michael-king-cannabis-palm-springs

Cannabis Use Associated With Improved Outcomes In Bipolar Patients

Cannabis use is associated with an alleviation of clinical symptoms in patients with bipolar disorder and does not negatively impact cognitive performance, according to clinical trial data published in the journal PLoS One.

Investigators with Harvard Medical School, Tufts University, and McLean Hospital in Massachusetts assessed the impact of marijuana use on mood symptomology and cognitive function in patients with bipolar disorder.

Authors reported that marijuana use was associated with lower scores of anger, tension, and depression, as well as higher levels of vigor in BPD patients. Subjects who used marijuana also showed no significant differences in cognitive performance compared to BPD subjects who abstained from the plant. The study is the first clinical trial to assess the impact of cannabis on both mood and neuropsychological performance in BPD patients.

Researchers concluded, “The current study highlights preliminary evidence that patients with BPD who regularly smoked marijuana reported at least short-term clinical symptom alleviation following marijuana use, indicating potential mood-stabilizing properties of marijuana in at least a subset of patients with BPD.”

 


Michael King is an experienced cannabis professional out of Palm Springs with a background in finance, private equity, real estate and consulting. He is currently a principal in one of the leading Cannabis consulting firms in the country Kings Garden

Read More
michael-king-cannabis-palm-springs

Study: Cannabis Smoke Exposure Doesn’t Significantly Impact Lung Health

Los Angeles, CA: Cannabis smoke exposure is not particularly detrimental to lung health and is not associated with the onset of lung cancer, emphysema, or COPD, according to data published in the journal Chest.

Donald Tashkin of UCLA’s David Geffen School of Medicine reviewed dozens of studies assessing cannabis smoke exposure and lung health, involving thousands of subjects.

He reports: “Although regular smoking of marijuana is associated with an increased risk of symptoms of chronic bronchitis and evidence of inflammation and injury involving the larger airways, lung function findings, although mixed, do not provide compelling evidence that habitual marijuana smoking in the manner and amount that it is generally smoked increases the risk of COPD, at least at the population level. Despite the presence of carcinogens in marijuana smoke in concentrations comparable with those that are found in tobacco smoke, the weight of evidence from well-designed epidemiologic studies does not support the concept that habitual marijuana use in the manner and quantity in which it is customarily smoked, when adjusted for tobacco, is a significant risk factor for the development of lung cancer.”

Studies also failed to show a relationship between cannabis smoking and decrements in lung function, and “argue against an association of marijuana with clinically significant emphysema.”

Tashkin’s findings are similar to those of past reviews finding that cannabis smoke exposure fails to possess the same sort of significant adverse pulmonary effects as does tobacco.

Original Press Release

 


Michael King is an experienced cannabis professional out of Palm Springs with a background in finance, private equity, real estate and consulting. He is currently a principal in one of the leading Cannabis consulting firms in the country.

Read More
michael-king-cannabis-marijuana-palm-springs

Marijuana Use Associated With Lower Diabetes Risk

The past use of cannabis is significantly associated with lower odds of diabetes in adults, according to data published in the journal Drug and Alcohol Review.

Investigators with the University of Toronto assessed the association between cannabis use and diabetes in a nationally representative sample while accounting for a range of potential confounders – including lifestyle behaviors, socio-demographics, and mental health disorders.

Compared to non-users, subjects with a history of cannabis use possessed an approximately 20 percent decreased the likelihood of diabetes. Those subjects with past-year marijuana use possessed an approximately 50 percent decreased risk.

“In sum, a decreased likelihood of diabetes for both lifetime and 12-month cannabis users versus non-users was found after accounting for a range of potential confounders, including mental health disorders,” authors concluded.

Although authors cautioned that “additional epidemiological studies … are needed before protective effects of cannabis can be suggested,” the study is one of several population studies identifying a positive association between lifetime cannabis consumption and a reduced risk for diabetes.

Read More
marijuana-senior-couple-michael-king-cannabis-palm-springs

Survey: Cannabis Use Becoming Common Among Older Adults

Aurora, CO: The use of cannabis is relatively common among those over the age of 65 who reside in a legal marijuana state, according to data published in the Journal of the American Geriatrics Society.

Investigators from the University of Colorado, Anschutz Medical Campus anonymously surveyed older adults at a pair of ambulatory geriatric primary care clinics in Colorado.

Thirty-two percent of respondents reported having used cannabis following legalization, and 16 percent reported that they were current users. Subjects were most likely to report using cannabis to mitigate symptoms of pain, anxiety, and depression, or to stimulate appetite.

Authors concluded: “[O]ur survey of ambulatory older adults from Colorado demonstrated that marijuana use in this population was common. Respondents reported using recreational marijuana to target a variety of medical symptoms and conditions with few reported adverse effects. Thus, it is prudent for primary care providers of older adults to inquire specifically about marijuana use before considering prescription changes or additions.”

Separate studies find that self-reported cannabis usage among older Americans is rising dramatically and that many seniors reduce their use of prescription medications, particularly opioids, following their marijuana use. According to clinical data assessing seniors’ long-term use of cannabis, consumption is safe and is associated with a “significant improvement” in subjects’ “overall quality of life.”

 

About Michael King Cannabis

Michael King is an experienced cannabis professional out of Palm Springs with a background in finance, private equity, real estate and consulting. He is currently a principal in one of the leading Cannabis consulting firms in the country.

Read More
canadians-allowed-travel-with-30-grams-cannabis-featured-michael-king-cannabis-palms-springs

Canadians Will Be Allowed to Travel With Up to 30 Grams of Cannabis

Only four months ago, Canada became the second country in the world to legalize recreational weed. Though the act passed slowly after two years of debate, this change for Canada means a new economy bolstered by marijuana. The Cannabis Act grants anyone over the age of 18 the right to possess up to one ounce of marijuana and grow up to four plants. And though this new bill still has its issues, the change has put forth new regulations for how Canadians can travel with their legal weed from province to province. This means as of October 17, when marijuana will be officially legal across The Great White North, Canadians will be allowed to fly with up to 30 grams of cannabis.

Imagining 30 Grams

30 grams of marijuana may be tough for the average consumer to imagine. It depends on the density of the bud and if it has already been rolled or ground. But bring to mind two outstretched hands and then use the imagination to fill it with loose buds. For the flower, that’s essentially what travelers can stow away in their luggage for inter-province travels. This amount seems surprisingly lenient, considering the legal state of cannabis elsewhere.  But if perhaps travelers pre-roll their stash, they can expect to bring about 60-75 joints. For someone who smokes 3-7 joints a day, that’s a two-week trip, with weed accommodated safely in their suitcase.

International Flights and Edibles—Don’t Even Try

Still, Canadian Minister of Transport Marc Garneau quickly warned against stashing that same 30 gram loot aboard an international flight. These passengers must instead abide by the laws of the country of destination.  Officials have not finalized consequences for people who bring weed through security on international flights. And though many US states now have legal marijuana, the drug remains illegal federally. Further, the U.S. government may ban investors and employees of cannabis companies from entering the United States.

Flowers could stink up a suitcase and travelers should resist the urge to pack less fragrant edibles. After all, edibles didn’t make it through this round of legalization. And though the edible scene in Canada now exists as a grey market, it definitely won’t be cleared through security. In short, travelers should feel comfortable packing up a 30 gram supply only if headed to another Canadian province—and only if it isn’t an edible.

Pot, Province by Province

But just because the domestic skies of Canada now allow cannabis, it doesn’t mean that each province has the same regulations. In fact, many of these areas of Canada differ concerning marijuana use. The amount, price, how to sell or market and the penalties for misuse all depend on the province. For instance, the consequences of driving under the influence in Nova Scotia appear much more severe than in Quebec.

Finally, comparing the price from province to province may be a good idea before packing up for traveling, if looking to save time or money. Say the bud costs less at the destination. Pack lighter and stow the maximum allotment on the return flight. Knowing these laws can help cannabis users make informed decisions about their newly legal usage.

Waiting for October 17, 2018

In less than two weeks, Canada will be the second country after Uruguay to legalize recreational marijuana. Until then, travelers should keep the pre-rolled joints and bags of flowers from their suitcases. But on that long-awaited day, whether a cannabis user in Montreal or Winnipeg, Toronto or Vancouver, travelers can confidently stand in domestic security lines at the airport. And unlike mostly anywhere else in the world, they can do so with up to 30 grams of weed in their carry-on.

About Michael King Cannabis

Michael King is an experienced cannabis professional out of Palm Springs with a background in finance, private equity, real estate and consulting. He is currently a principal in one of the leading Cannabis consulting firms in the country.

Read More

Daily Cannabis Use Associated With Grater Retention Rates Among Subjects Undergoing Opioid Agonist Treatment

Daily cannabis users undergoing therapy for opioid dependence are far more likely to complete their treatment regimen than are non-users, according to clinical trial data published in the journal Addiction.

Canadian investigators assessed retention rates among 820 subjects enrolled in either methadone or buprenorphine/naloxone-based treatment programs. Researchers reported, “[I]ndividuals initiating OAT (opioid agonist treatment) were approximately 21 percent more likely to be retained in treatment at six months if they reported ≥ daily use of cannabis. This finding persisted after adjustment for a range of confounders.”

They concluded, “Given the well-known mortality risk reduction benefit of sustained engagement in OAT, findings from the present study alongside prior research evidence support the urgent need for clinical research to evaluate the therapeutic potential of cannabinoids as adjunctive treatment to OAT to address the escalating opioid-overdose epidemic.”

Prior observational studies have consistently reported lower rates of opioid abuse and mortality in jurisdictions where marijuana access is legal.

For more information, contact Paul Armentano, NORML Deputy Director, at: paul@norml.org. Full text of the study, “High-intensity cannabis use is associated with retention in opioid agonist treatment: a longitudinal analysis,” appears in Addiction. NORML’s fact-sheet, “Relationship between marijuana and opioids,” is online.

Original Press Release

 

About Michael King Cannabis

Michael King is an experienced cannabis professional out of Palm Springs with a background in finance, private equity, real estate and consulting. He is currently a principal in one of the leading Cannabis consulting firms in the country.

Read More
chai-dispensary-santa-cruz-capitola-michael-king-cannabis

Canadian Cannabis Company Captor Capital Buys San Jose Dispensary for $6 Million

Leading Santa Cruz Dispensary Acquired by Captor Capital

Adding Chai Cannabis continues to increase presence in California retail cannabis market September 18, 2018

TORONTO, Sept. 18, 2018 (GLOBE NEWSWIRE) — Captor Capital Corp. (“Captor” or the “Company”) (CSE: CPTR; FRANKFURT: NMV;USOTC:NWURF) announced today it has completed its previously announced acquisition of a dispensary in Santa Cruz, California, Chai Cannabis Inc. (“Chai”). Chai also possesses a license permitting cannabis delivery within the greater Santa Cruz area. Adding this dispensary, one of the most popular in the area (unaudited revenues of USD$8.4 in 2017), is expected to materially increase total revenues from Captor’s retail cannabis investments.

Chai was acquired for a total consideration of USD$6,015,000, of which USD$4,390,950 was payable in cash closing, USD$721,800 of which was in the form of a promissory note and USD$902,250 was paid in shares of Captor. The portion of the consideration paid in Captor shares was converted into approximately C$1,187,722 and 7,662,722 Captor Shares were issued at a deemed issue price of $0.155.

Dispensary renovations are set to begin shortly that will triple Chai’s sales floor space. The newly renovated space will allow Chai to carry a much wider range of flowers, edibles, extracts, and other cannabis products. Chai will remain open during the renovations and it is not expected to impact the dispensary’s operations. Manager of Chai, Josh Lechner, has been successfully operating the dispensary since it opened in 2014 and will continue on in this role.

The Chai brand adds a unique retail experience to the consumer which complements Captor’s premium branded MedMen (MMEN.CN), stores in West Hollywood and Santa Ana. The acquisition of Chai continues Captor’s business plan to aggressively invest in California’s retail; cannabis industry. Captor’s investment in this profitable dispensary represents a fantastic growth opportunity. We believe the Santa Cruz area with more than 4 million tourists visiting each year will become a growing retail cannabis market.”

About Captor Capital

Captor Capital Corp. is a Canadian firm focused on the cannabis sector listed on the Canadian Securities Exchange, the OTC, and the Frankfurt Stock Exchange. A vertically integrated cannabis company, Captor provides recreational and medical marijuana based products to consumers via its leading brands and dispensary locations. Listed on the Canadian Securities Exchange, the OTCUSA, and the Frankfurt Stock Exchange, Captor owns and operates advanced growing facilities which produce consistent high-quality contaminant free marijuana for its customers, as well as other high demand cannabis-based goods for consumption. 
The company follows a strategy of acquiring cash flowing established companies and organizations with growth potential that require capital to scale. Captor currently has a number of revenue generating cannabis investments including two wholly owned branded MedMen dispensaries – the world famous West Hollywood location and the showpiece Orange County dispensary in Santa Ana. Captor Capital is currently looking at additional revenue generating investments in the cannabis space and will be updating the market in due course.

 

Original Press Release


About Michael King

Michael King is an experienced professional with a background in finance, private equity, real estate and consulting. He is currently a principal in one of the leading Cannabis consulting firms in the country based out of Palm Springs — Kings Garden Inc.

Read More
Aurora Cannabis Michael King Cannabis Palm Springs

Aurora Cannabis to Acquire Uruguayan Medical Cannabis Provider ICC Labs for $290 Million in Stock

EDMONTON and VANCOUVER, Sept. 10, 2018 /CNW/ – Aurora Cannabis Inc. (Aurora or the Company) (TSX: ACB) (OTCQB: ACBFF) (Frankfurt: 21P; WKN: A1C4WM) and ICC Labs Inc. (TSX-V: ICC) (ICC) announced today that the companies have entered into a definitive arrangement agreement  pursuant to which Aurora intends to acquire all of the issued and outstanding common shares of ICC (the ICC Shares) for $1.95 per share (payable in common shares of Aurora (the Aurora Shares) (the Share Consideration), reflecting an aggregate purchase price of approximately $290 million (the Transaction). The Transaction has been unanimously approved by the Board of Directors of each ICC and Aurora.

Strategic Rationale

Led by CEO Alejandro Antalich, a widely-recognized leader in the South American cannabis market with over 25 years of experience in the pharmaceutical sector, the acquisition of ICC will establish Aurora as the industry leader in South America, a continent with over 420 million people. ICC presently has over 70% market share in Uruguay, the first country in the world to legalize cannabis for adult consumer use. In addition, ICC holds licenses in Colombia for the production of medical cannabis.

The Transaction, once approved, creates a strong foundation for expansion, and will leverage ICC’s first mover advantage in South America, bringing significant low-cost production capacity, a well-diversified product portfolio, and extensive distribution channels throughout South America and internationally.

ICC brings Aurora, among other strategic synergies, the following:

Significant, low-cost Capacity

  • Significant expansion of low-cost production and processing capacity: ICC is expanding rapidly, with both established facilities and a number of projects nearing completion to bring the estimated production capacity to over 450,000 kg per annum, adding significant value to Aurora’s funded footprint:
    • Two greenhouse facilities: currently operational – approximately 92,000 square feet
    • Three outdoor grow sites, with a potential total area of over 800 acres, 590 acres of which are in Uruguay and which are being prepared for cultivation start later this calendar year
    • Two facilities currently under construction, adding 124,000 square feet of greenhouse production in Columbia and a 1,000,000 sq ft facility in Uruguay

Strong Foundation to Capitalize on the Significant Global CBD Wellness Market Opportunity

  • CBD Rich Production: Uruguay is the only country where regulations currently permit the cultivation of CBD-rich hemp on a commercial scale, allowing licensed producers to grow hemp with THC concentrations of up to 1%, providing a significant yield advantage over global competitors. ICC’s deep background in pharma and the ability to grow low-cost CBD-rich hemp at very large scale positions the companies exceptionally well to capitalize on global opportunities in the high-growth CBD wellness market.
  • CBD Brand and Distribution: ICC recently launched its BIDIOL brand of CBD products, and is developing a broad international distribution network, including a presales agreement to export product to Mexico, a market with over 125 million people.
  • Significant Extraction Capacity: ICC is progressing well towards the completion of a state-of-the-art large-scale extraction facility with the capacity to process 150,000 kg of CBD feed per annum. Phase I of the facility is anticipated to be completed in October 2018, with the full facility online and operational by late 2018.
  • Free Trade: ICC’s new CBD extraction facility is strategically located approximately five minutes from the Canelones international airport and within Uruguay’s “Science Park” free trade zone, exempting facility exports from any applicable local tax on exports and imports.

Science, High-margin Products and Strong Genetics

  • The First South American GMP Compliant Science Lab: ICC is close to completing South America’s first state-of-the-art cannabis science laboratory, designed to the highest international standards and in compliance with applicable GMP standards. Soon to be certified, the facility will provide an early mover advantage over other producers in South America. to drive sales to international cannabis markets.
  • Product Diversification: ICC are leaders in South America, offering a broad portfolio of dried flower and higher margin products, including tablets, softcaps, ointments, creams, drops, infused syrups, and patches.
  • Genetics: ICC have secured a portfolio of high CBD strains that are exclusive to ICC in South America, and are highly sought after.

Anticipated benefits for ICC shareholders

In addition to the benefits described above, related to the combined entity, ICC shareholders will receive the following additional benefits:

  • Premium: The Share Consideration represents a premium of approximately 34% on the 20 day volume-weighted average trading price of ICC Shares on the TSX-V for the period ending August 22, 2018, the last trading day prior to ICC issuing a news release in respect of a media report speculating as to a potential transaction involving the acquisition of ICC.
  • Liquidity: Aurora Shares are listed and posted for trading on the TSX, providing ICC shareholders with potentially greater liquidity.
  • Aurora Shares: ICC shareholders, who will represent approximately 3.6% of outstanding Aurora Shares after giving effect to the Transaction, will have the opportunity to participate in the future potential increase in the value of Aurora, one of the world’s largest vertically integrated cannabis companies with a well-developed international footprint across five continents.

Neil Belot, Chief Global Business Development Officer, added “ICC, as the first company globally to be federally legalized for the sale of cannabis for adult consumer use, is a trailblazer in, and has set the example for the responsible production and distribution to this exciting market. The ICC/Aurora combination is the trusted partner for governments and other stakeholders to develop opportunities in emerging South American cannabis markets. We are extremely excited to be working with Alejandro and the team at ICC, and look forward to jointly pursuing a wide variety of opportunities in the adult consumer use, medical and CBD wellness markets.”

Alejandro Antalich, CEO of ICC added, “ICC was the first company in the world to receive a cannabis production license for adult consumer use, making Uruguay the first country globally in the modern era to legalize cannabis. This has provided us with significant early mover advantage. Combining with Aurora, its industry-leading plant, medical and product development science teams, broad international reach, and strong brands, positions us well to extend our leadership in the South American cannabis markets and the emerging global cannabis industry. The complementary nature of the two organizations and the shared philosophies made this an ideal match for us to realize our ambitious growth plans. This is a value-maximizing transaction that provides our shareholders with a significant premium and an exciting opportunity to participate in the upside of Aurora, one of the largest and fastest growing cannabis companies in the world. With multiple initiatives, such as our expanding international operations and our state-of-the-art science lab near to completion, it is time for ICC to move to the next level, and we believe that Aurora is an ideal partner to achieve this with.”

Terms of the Transaction

The Transaction will be effected by way of a plan of arrangement under the Business Corporations Act (British Columbia) (the Arrangement). Under the terms of the Transaction, each shareholder of ICC (ICC Shareholder) will receive $1.95 per ICC Share, payable in Aurora Shares valued at the volume-weighted average trading price of Aurora Shares on the TSX during the 20 trading day period ending the second to last trading day on the TSX immediately prior to the Effective Date (as defined in the Arrangement Agreement), being the date the Transaction is completed (the Aurora Share Price).

Pursuant to the terms of the Transaction, based on the volume-weighted average trading price of Aurora Shares on the TSX during the 20 trading day period ending September 7, 2018 an ICC Shareholder would receive 0.2448 Aurora Shares for each ICC Share held, resulting in Aurora issuing approximately 36.2 million Aurora Shares (fully diluted, treasury method) in connection with the Transaction, representing approximately 3.6% of outstanding Aurora Shares after giving effect to the Transaction (actual number of shares received and issued will be based on the volume-weighted average trading price of Aurora Shares on the TSX during the applicable 20 day period preceding the completion of the Transaction).

The Transaction is subject to the approval of the Supreme Court of British Columbia and the approval of two-thirds of the votes cast by ICC Shareholders at a special meeting to be called of ICC Shareholders to approve the Transaction (the ICC Special Meeting).

Union Group International Holdings Limited (Union Group) has entered into a support agreement with Aurora to, among other things, vote the ICC Shares owned by it in favor of the Transaction and to otherwise support its completion, subject to the terms and conditions of such support agreement.  Union Group holds approximately 29% of the issued and outstanding ICC Shares.  All of the directors and senior officers of ICC (who hold in the aggregate approximately 0.4% of the issued and outstanding ICC Shares on a non-diluted basis) have entered into similar support agreements with Aurora pursuant to which they have agreed, among other things, to support the Transaction and vote their ICC Shares in favor of the Transaction.

The Transaction remains subject to certain other closing conditions including the receipt of certain approvals (including certain Uruguayan regulatory approvals and the consent of Aurora’s lenders), and the satisfaction of certain customary closing conditions. Approval by shareholders of Aurora is not required.

The Board of Directors of ICC (the ICC Board) unanimously recommends that ICC Shareholders vote in favor of the resolution to approve the Arrangement, which will be the subject of the ICC Special Meeting expected to be held in the fourth quarter of 2018. The recommendation of the ICC Board is supported by a fairness opinion from each of Canaccord Genuity Corp. and INFOR Financial Inc. to the effect that, as of the date of each opinion, and subject to the assumptions, limitations, and qualifications on which each such opinion is based, the consideration to be received by ICC Shareholders pursuant to the Transaction is fair, from a financial point of view to such shareholders.

The Arrangement Agreement provides for, among other things, the ICC Board being able to consider a superior proposal in certain circumstances and a right in favor of Aurora to match any superior proposal. The Arrangement Agreement also provides for the payment by ICC of a termination fee of $9,500,000 in favor of Aurora in certain circumstances. In addition, the Arrangement Agreement provides that, under certain circumstances, where the Transaction is not completed because of the failure of Aurora to obtain certain consents, Aurora would be required to (i) reimburse ICC’s expenses up to $750,000, and (ii) pay a reverse break fee to ICC in the amount of $1,250,000.

It is currently expected that, subject to receipt of all regulatory, court, shareholder and other approvals, and the satisfaction or waiver of all conditions, the Transaction will be completed in the fourth quarter of 2018.

Further information regarding the Transaction will be included in ICC’s management information circular to be mailed to ICC Shareholders in advance of the ICC Special Meeting and in ICC’s material change report in respect of the announcement of the Transaction, each of which will be filed with the Canadian securities regulators and will be available under ICC’s profile at www.sedar.com.

Financial and Legal Advisors

Canaccord Genuity Corp. is acting as financial advisor to ICC and Norton Rose Fulbright Canada LLP is acting as legal counsel to ICC. INFOR Financial Inc. was also engaged by the ICC Board as an independent financial advisor to provide an independent fairness opinion in respect of the Transaction.
McMillan LLP is acting as legal counsel to Aurora.

About Aurora

Headquartered in Edmonton, Alberta, Canada with funded capacity in excess of 500,000 kg per year and sales and operations in 14 countries across five continents, Aurora is one of the world’s largest and leading cannabis companies. Aurora is vertically integrated and horizontally diversified across every key segment of the value chain, from facility engineering and design to cannabis breeding and genetics research, cannabis and hemp production, derivatives, high value-add product development, home cultivation, wholesale and retail distribution.

Highly differentiated from its peers, Aurora has established a uniquely advanced, consistent and efficient production strategy, based on purpose-built facilities that integrate leading-edge technologies across all processes, defined by extensive automation and customization, resulting in the massive scale production of high-quality product at ultra-low costs. Intended to be replicable and scalable globally, these production facilities are designed to produce cannabis of significant scale, with high quality, industry-leading yields, and ultra-low per gram production costs. Each of Aurora’s facilities is built to meet European Union (EU) GMP standards, and its first production facility, the recently acquired MedReleaf Markham facility, and its wholly owned European medical cannabis distributor Aurora Europe GmbH, have achieved this level of certification.

In addition to the Company’s rapid organic growth and strong execution on strategic M&A, which to date includes 10 companies acquired – MedReleaf, CanvasRx, Peloton Pharmaceutical, Pedanios, H2 Biopharma, Urban Cultivator, BC Northern Lights, Larssen Greenhouses, CanniMed Therapeutics, and Anandia – Aurora is distinguished by its reputation as a partner of choice and employer of choice in the global cannabis sector, having invested in and established strategic partnerships with a range of leading innovators, including: The Green Organic Dutchman Holdings Ltd. (TSX: TGOD), Radient Technologies Inc. (TSXV: RTI), Hempco Food and Fiber Inc. (TSXV: HEMP), Cann Group Ltd. (ASX: CAN), Micron Waste Technologies Inc. (CSE: MWM), Choom Holdings Inc. (CSE: CHOO), Namaste Technologies Inc. (TSXV: N), Evio Beauty Group (private), Wagner Dimas (private), CTT Pharmaceuticals (OTCC: CTTH), Capcium Inc. (private), and Alcanna Inc. (TSX: CLIQ).

Aurora’s Common Shares trade on the TSX under the symbol “ACB”, and are a constituent of the S&P/TSX Composite Index.

For more information about Aurora, please visit our investor website, investor.auroramj.comTwitterFacebook orInstagram.

About ICC

ICC is a fully licensed producer and distributor of medicinal cannabinoid extracts, recreational cannabis, and industrial hemp products in Uruguay as well as a fully licensed producer of medicinal cannabis in Colombia. The Company has active operations in Uruguay and is focused on becoming the worldwide leading producer of cannabinoid extracts, giving support and promoting responsible use for medicinal purposes, backed by scientific research and innovation, while following strict compliance with standards for quality and safety.

For more information, please visit www.icclabs.com.

 

Article Via New Cannabis Ventures

 

About Michael King Cannabis

Michael King is an experienced cannabis professional out of Palm Springs with a background in finance, private equity, real estate and consulting. He is currently a principal in one of the leading Cannabis consulting firms in the country.

Read More
study-suggests-cbd-may-have-antipsychotic-effect-high-risk-individuals-featured Michael King Cannabis Palm Springs

Study Suggests CBD May Have Antipsychotic Effect in Individuals

The psychiatric research journal JAMA Psychiatry has just published a new study suggesting CBD could have antipsychotic effects in individuals at clinical high risk of psychosis. The study builds off compelling prior research demonstrating CBD’s therapeutic effects. Titled “Effect of Cannabidiol on Medial Temporal, Mid-brain, and Striatal Dysfunction in People at Clinical High Risk of Psychosis,” the randomized clinical trial sheds important light not just on whether or not CBD has calming cognitive effects, but also how it produces them.

Psychiatrists Investigate the Underlying Causes for CBD’s Therapeutic Effects

What are the neurocognitive mechanisms that underlie the putative therapeutic effects of cannabidiol in psychosis? In other words, does CBD really help treat psychosis? And if so, how? Such are the questions motivating a new study published in JAMA Psychiatry.

Researchers began with the premise that cannabidiol (CBD) has antipsychotic effects in humans. Exactly how it has that effect on the brain isn’t fully understood. Psychiatrists study the chemical reactions that lead to or stem from atypical mental states. For this study, researchers wanted to try to isolate the specific chemical alterations that give CBD its therapeutic and potentially antipsychotic effects.

To do so, the study examined the effects of CBD in 33 individuals at clinical high risk (CHR) of psychosis. Previous studies have identified the regions of the brain that become perturbed in individuals with psychosis and at CHR. So the JAMA study had a hypothesis: maybe CBD attenuates, or lessens, those disturbances in the parts of the brain associated with psychosis.

Study’s Findings Confirm CBD’s Influence on Brain Regions Implicated in Psychosis

The study’s 33 CHR participants were part of a double-blind randomized clinical trial with 19 healthy control individuals. Some participants received a single, 600 mg oral dose of cannabidiol; others, no CBD or a placebo. Researchers examined how the CBD affected the striatum, medial temporal cortex, and midbrain—the target brain regions.

The investigation revealed that all three brain regions experienced modulated activation as a result of the CBD. Using an MRI while participants performed a verbal learning task, researchers measured brain activation alongside healthy control individuals who took no CBD, and high-risk patients who received a placebo. What they found was that CHR patients who took CBD had activation levels about in the middle between healthy individuals with no disturbances and CHR patients who took no CBD.

In short, CBD did have the attenuating effects researchers had hypothesized. The oral dose of cannabidiol helped normalize dysfunction in all three brain regions. And that means the study may have identified one of the mechanisms responsible for CBD’s therapeutic benefits.

While the study’s findings have implications for psychiatric medicine and treating individuals at high risk for psychosis, it has wider importance for anyone interested in the effects of cannabis on mental health.

There are studies that have drawn links between regular and frequent cannabis use and the development of psychosis. Others have linked psychosis with changes to the endocannabinoid system, whether cannabinoid-stimulated or not. At the same time, research shows CBD, a non-psychoactive cannabinoid, has an almost opposite neural and behavioral effect to THC. With this latest study, scientists now know more about why that is.

 

article via High Times

 


About Michael King

Michael King is an experienced professional with a background in finance, private equity, real estate and consulting. He is currently a principal in one of the leading Cannabis consulting firms in the country based out of Palm Springs — Kings Garden Inc.

Read More